Table 4 Kaplan–Meier survival estimation of mean survival and hazard ratios (HRs) among different genotypes
Genotype | N | Number of events | Mean survival (in months) | Log rank P value | HR (95Â % CI) | P value |
|---|---|---|---|---|---|---|
Ghrelin Arg51Gln | ||||||
GG | 164 (63.8) | 37 (67.3) | 37.2 ± 1.4 | 0.691 | Reference |  |
GA | 75 (29.2) | 15 (27.3) | 36.1 ± 1.7 |  | 0.8 (0.4–1.5) | 0.557 |
AA | 18 (7.0) | 3 (5.4) | 36.5 ± 2.8 |  | 0.6 (02–2.1) | 0.489 |
Ghrelin Leu72Met | ||||||
CC | 178 (69.3) | 38 (69.1) | 37.9 ± 1.3 | 0.061 | Reference |  |
CA | 51 (19.8) | 7 (12.7) | 36.6 ± 1.6 |  | 0.6 (0.2–1.3) | 0.208 |
AA | 28 (10.9) | 10 (18.2) | 29.7 ± 3.3 |  | 1.8 (0.8–3.6) | 0.09 |
UCP2 I/D | ||||||
DD | 149 (57.6) | 28 (50.9) | 35.2 ± 1.2 | 0.345 | Reference |  |
ID | 70 (27.6) | 19 (34.5) | 35.5 ± 2.2 |  | 1.5 (0.8–2.7) | 0.151 |
II | 38 (14.8) | 8 (14.5) | 28.7 ± 1.95 |  | 1.2 (0.5–2.6) | 0.651 |
Leptin-2548 G/A | ||||||
GG | 90 (35.0) | 22 (40.0) | 32.5 ± 1.6 | 0.582 | Reference |  |
GA | 99 (38.5) | 19 (34.5) | 38.9 ± 1.6 |  | 0.7 (0.4–1.4) | 0.338 |
AA | 68 (26.5) | 14 (25.5) | 35.2 ± 1.7 |  | 0.7 (0.3–1.5) | 0.456 |
Combined analysis | ||||||
Group 1 | 107 (41.6) | 26 (47.3) | 32.5 ± 1.3 | 0.79 | Reference |  |
Group 2 | 150 (58.3) | 29 (52.7) | 38.3 ± 1.4 |  | 0.93 (0.5–1.5) | 0.792 |
CRP category | ||||||
Non-inflamed | 156 (60.7) | 30 (54.5) | 35.9 ± 1.3 | 0.561 | Reference | 0.565 |
Inflamed | 101 (39.3) | 25 (45.5) | 37.6 ± 1.5 |  | 1.1 (0.6–1.9) |  |
SGA categories | ||||||
Normal | 78 (30.4) | 9 (16.4) | 38.0 ± 1.2 | 0.004* | Reference |  |
Mild | 38 (14.8) | 7 (12.7) | 35.2 ± 2.3 |  | 1.8 (0.6–4.8) | 0.243 |
Moderate | 100 (38.9) | 24 (43.6) | 37.1 ± 1.7 |  | 2.2 (1.1–4.8) | 0.03* |
Severe | 41 (15.9) | 15 (27.3) | 23.5 ± 2.3 |  | 4.1 (1.8–9.4) | 0.001* |
Period of dialysis | ||||||
<1 year | 170 (66.1) | 38 (69.1) | 36.3 ± 1.5 | 0.618 | Reference |  |
≥1 year | 87 (33.9) | 16 (29.9) | 34.5 ± 1.8 |  | 0.8 (0.6–1.2) | 0.438 |